Lexeo Therapeutics financials
$3.42+8.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$28.0M | -$22.3M | -$23.1M | -$21.6M | -$30.7M | -$33.8M | -$27.4M | -$31.5M | -$23.6M | -$23.3M | -$15.0M |
| Net income | -$25.9M | -$20.2M | -$20.9M | -$20.3M | -$26.1M | -$32.7M | -$25.9M | -$29.5M | -$21.2M | -$21.7M | -$14.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.30 | $-0.25 | $-0.27 | $-0.33 | $-0.60 | $-0.99 | $-0.78 | $-0.89 | $-0.64 | $-0.77 | $-0.86 |
| EBITDA | -$27.9M | -$22.3M | -$23.0M | -$21.7M | -$30.6M | -$33.7M | -$27.3M | -$31.6M | -$23.4M | -$23.1M | -$15.1M |
| Operating cash flow | -$17.6M | -$21.1M | -$20.1M | -$29.5M | -$27.2M | -$21.7M | -$28.3M | -$17.8M | -$20.2M | -$14.9M | -$14.0M |
| Free cash flow | -$17.6M | -$21.2M | -$20.1M | -$29.8M | -$27.3M | -$21.7M | -$28.3M | -$17.9M | -$20.4M | -$15.1M | -$14.1M |
| Diluted shares | 85.6M | 81.2M | 76.9M | 61.0M | 43.6M | 33.1M | 33.1M | 33.1M | 33.0M | 28.0M | 16.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $92.8M | $71.8M | $63.0M | $41.0M | $35.5M | $28.9M |
| Short-term investments | $118.9M | $121.3M | $118.8M | $81.8M | $97.4M | $70.9M |
| Total debt | $584.0K | $726.0K | $845.0K | $1.0M | $1.1M | $1.2M |
| Total assets | $254.9M | $250.4M | $268.7M | $143.8M | $176.1M | $125.7M |
| Total liabilities | $19.8M | $18.9M | $22.0M | $23.0M | $37.9M | $37.6M |
| Shareholders' equity | $235.1M | $231.5M | $246.7M | $120.8M | $138.2M | $88.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology